Posts by: Steve Bryson PhD

Steve Bryson PhD

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.

October 29, 2020October 29, 2020

Study Shows Benefits of Early Growth Hormone Therapy in PWS Children

News

Starting growth hormone therapy before the first birthday has significant benefits over beginning treatment at an older age in children with Prader-Willi syndrome (PWS), an analysis found. Children treated early ... Read more

September 29, 2020September 29, 2020

Uric Acid Lower in Adults With PWS and Obesity, Study Shows

News

Levels of uric acid in the blood are lower in adults with Prader-Willi syndrome (PWS) who are obese than in people without PWS but who also are obese, a study ... Read more

July 14, 2020July 14, 2020

High Protein Meals Boost GLP-1 Hormone Known to Suppress Appetite in PWS Children, Study Finds

News

High protein meals induce the secretion of the insulin-stimulating hormone glucagon-like peptide 1 (GLP-1) in children with Prader-Willi syndrome (PWS), suggesting that these kinds of meals may help suppress ... Read more

June 23, 2020June 23, 2020

Improved Height, Body Composition Found in PWS Patients Treated With Growth Hormone

News

Growth hormone therapy improves height and body composition while lowering body mass index (BMI) in people with Prader-Willi syndrome (PWS), according to a review of clinical trials. The study, “Growth hormone ... Read more

June 4, 2020June 4, 2020

Tracking Eye Movements Can Measure Chronic Desire to Overeat

News

Tracking the eye movements of children with Prader-Willi syndrome (PWS) may be a non-invasive, low-cost, and reliable method to assess their chronic desire to overeat, known as hyperphagia, a ... Read more

November 14, 2019

Phase 2b/3 Trial of Livoletide Completes Enrollment of PWS Patients Ages 8 to 65

News

A Phase 2b/3 clinical trial of livoletide, a treatment candidate for excessive eating in people with Prader-Willi syndrome (PWS), has completed recruitment of participants who are 8 to 65 ... Read more

October 10, 2019October 10, 2019

Research Supported by PWS Foundation to Examine Cause of Behavioral Problems, Possible Treatment

News

A grant winner’s research may help to advance a possible treatment of behavioral problems like temper outbursts in Prader-Willi syndrome patients. The treatment, an approved medication but not for ... Read more

September 24, 2019September 24, 2019

Higher Dose of Tesomet Effective in PWS Adolescents, Saniona Reports

News

Saniona announced that adolescents with Prader-Willi syndrome (PWS) showed improvements in weight, body mass index (BMI), and hyperphagia score — measuring appetite reduction — when treated with the investigational therapy ... Read more

August 20, 2019August 20, 2019

Patients Treated With Growth Hormone Score Higher on Vocabulary IQ Tests, Study Shows

News

People with Prader–Willi syndrome (PWS) who received growth hormone therapy had significantly higher vocabulary IQ scores compared with those who did not have the treatment, a study shows. The ... Read more

August 6, 2019August 6, 2019

Millendo Therapeutics Announces Phase 2b/3 Trial Assessing Promising PWS Therapy, Livoletide

News

A potential new treatment for Prader-Willi syndrome (PWS) will be tested in the large, international clinical trial ZEPHYR, in a partnership between Millendo Therapeutics and several research centers, including The ... Read more